---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-24-000040"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:24:41.492659+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics reports Q3 net loss of $15.6M; BDTX-1535 Phase 2 data

## Summary
- Net loss of $15.6M in Q3 2024 vs $23.0M in Q3 2023; cash and investments $112.7M, sufficient into Q2 2026.
- R&D expenses decreased to $12.9M from $16.2M YoY due to workforce efficiencies and reduced early discovery.
- Announced restructuring in Oct 2024 to prioritize BDTX-1535 and extend cash runway; deprioritized BDTX-4933.
- Initial Phase 2 data for BDTX-1535 in EGFRm NSCLC: 42% ORR in 19 patients with osimertinib resistance mutations; DOR ~8+ months in first 3 PRs.
- Expects to disclose initial Phase 2 data in first-line and updated recurrent setting data plus FDA feedback in Q1 2025.

## SEC filing metadata
- accession: 0001701541-24-000040
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000040/0001701541-24-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000040/bdtx-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-24-000040
- JSON: https://secwatch.observer/filing/0001701541-24-000040.json
- Plain text: https://secwatch.observer/filing/0001701541-24-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.